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Abstract 
Allogeneic hematopoietic stem cell transplantation (HSCT) has become a standard 
procedure in the management of malignant and nonmalignant diseases. Successful HSCT 
depends on immunosuppression, which is necessary to avoid graft rejection and graft-
versus-host disease (GvHD) until the donor-derived immune system reconstitutes. The 
duration depends on the tissue HLA-type (human leukocyte antigen) between donor and 
patient, and intensity of chemotherapy or irradiation prior to transplantation. As a result, 
patients are highly susceptible to a wide range of viral infections, and adenovirus (ADV), for 
example, has become the most common viral pathogen responsible for significant post-
transplantation morbidity and mortality in pediatric patients.  
Antiviral drugs seem to control but not cure the infection and exhibit undesired side effects. 
However, it was shown that recovery of ADV-specific T cells correlates with the clearance of 
ADV infections. Since the frequency of ADV-specific T cells of healthy ADV-seropositive 
individuals is very low in fresh blood, we established a very fast method to expand and detect 
ADV-specific T cells. We repeatedly stimulated peripheral blood mononuclear cells (PBMCs) 
with ADV-specific antigens within a 12 day culture period. After expansion, the number of 
ADV-specific T cells was 1-2 log increased and could then easily be detected by HLA-peptide 
multimers. Furthermore, the expansion protocol was optimized by the addition of interleukin 
(IL) -15, which was superior (3,5 fold) over the treatment with IL-2 or IL-7.  
Independent of the interleukins used, after in vitro expansion, 96% of all cells exhibited an 
effector immunophenotype. However, about 3% of all cells maintained a central memory 
phenotype, providing long-lived in vivo protection against viral infections.  
Next, we confirmed that expanded ADV-specific T cells are functionally active by showing 
increased secretion of interferon-gamma (IFN-γ) and expression of activation markers such 
as CD137 and CD107a after stimulation with the virus-specific antigen. Additionally, 
cytotoxicity was observed against both autologous and partially mismatched antigen-pulsed 
target cells but was highly reduced against completely mismatched target cells, indicating a 
very low likelihood of alloreactivity of expanded cells. However, to completely reduce 
possible residual alloreactivity without influencing functional activity, expanded cells have 
been irradiated. Strikingly, irradiated ADV-specific T cells showed similar antigen-specific 
IFN-γ response and cytotoxicity as compared to non-irradiated cells without alloreactivity. 
These results demonstrate a milestone in the field of adaptive T cell transfer and could have 
major implications for patients suffering from viral infections after HSCT.   
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Zusammenfassung 
Allogene hämatopoetische Stammzellentransplantationen (HSZT) haben sich als 
Standardbehandlung für maligne und nicht-maligne Erkrankungen etabliert. Die Erfolgsrate 
einer HSZT wird stark vom Grad der Immunsuppression beeinflusst, welche notwendig ist 
um die Transplantatabstoßung und Transplantat-gegen-Wirt Reaktion (graft-versus-host 
disease, GvHD) zu verhindern, bis sich das neue (vom Spender stammende) Immunsystem 
vollständig entwickelt hat. Die dafür erforderliche Zeit hängt vom Gewebe HLA-Typ zwischen 
Spender und Empfänger und der Intensität der Chemotherapie oder Bestrahlung vor Beginn 
der Transplantation ab. In diesem Zeitraum sind die Patienten einem erhöhtem Risiko für 
virale Infektionen ausgesetzt. Der humane Adenovirus (ADV) gilt dabei als der häufigste 
virale Erreger, der eine signifikant erhöhte Erkrankungswahrscheinlichkeit und 
Sterblichkeitsrate bei Kindern nach Transplantationen aufweist. 
Antivirale Medikamente können die Infektion in den meisten Fällen nur eindämmen, jedoch 
nicht heilen, zudem weisen diese viele unerwünschte Nebenwirkungen auf. Es konnte jedoch 
gezeigt werden, dass das Auftreten von ADV-spezifischen T Zellen mit der Beseitigung der 
ADV Infektion korreliert. Die Frequenz ADV-spezifischer T Zellen von gesunden ADV-
seropositiven Personen ist im Blut sehr gering. Aus diesem Grund entwickelten wir ein 
Protokoll um diese Zellen anzureichern und nachzuweisen. Dafür wurden mononukleare 
Zellen des peripheren Blutes isoliert und mehrmals innerhalb einer 12 Tage Kultivierung mit 
einem ADV-spezifischen Antigen stimuliert. Nach der Expansion war die Zahl der ADV-
spezifischen T Zellen um 1-2 log Stufen angestiegen und konnte mittels HLA-Peptid 
Pentamer nachgewiesen werden. Weiters konnten wir die Anreicherung durch eine 
Interleukin (IL) -15 Zugabe verbessern, was die Expansion um das 3.5 fache im Vergleich zu 
IL-2 und IL-7 Behandlung erhöhte. 
Unabhängig von der Interleukingabe entwickelten 96% aller angereicherten ADV-
spezifischen Zellen einen Effektor Phänotyp. Wir konnten jedoch auch zeigen, dass 3% als 
Zentrale-Gedächnis-T-Zellen (central memory T cells, TCM) erhalten bleiben und somit einen 
lebenslangen Schutz gegen virale Infektionen gewährleisten.  
Im nächsten Schritt analysierten wir die Funktionalität von angereicherten ADV-spezifischen 
T Zellen durch den Nachweis der gesteigerte Sekretion von Interferon-gamma (IFN-γ) und 
der Expression von Aktivierungsmarkern wie CD137 und CD107a, nach der Stimulation mit 
dem Virus-spezifischen Antigen. Die Analyse der Zytotoxizität zeigte, dass autologe, aber 
auch nur zum Teil übereinstimmenden Antigen-beladenen Zielzellen mit einer hohen 
Inzidenz eliminiert wurden. Vollständig unpassende und unbeladene Zielzellen wurden 
dagegen nicht erkannt, was auf eine spezifische Erkennung mit einem geringen Potential für 
Alloreaktivität schließen lässt. Um die Gefahr einer GvHD vollständig zu reduzieren, ohne 
dabei die Funktionalität zu beeinflussen, wurden die angereicherten Zellen bestrahlt.  
 10 
Bemerkenswerterweise zeigten bestrahlte ADV-spezifische T Zellen ähnliche Antigen-
spezifische IFN-γ Reaktionen wie unbestrahlte Zellen, ebenso war die Zytotoxizität, welche 
ein Indiz für Alloreaktivität wäre, im Vergleich nicht verändert.  
Diese Ergebnisse liefern wichtige Informationen für ein besseres Verständnis auf dem Gebiet 
der Adaptiven-T-Zellenübertragung und verbessern die Prognosen bei der Bekämpfung von 
viralen Infektionen nach HSZT.  
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1 Introduction 
1.1 Hematopoietic stem cell transplantation and its potential risks 
Hematopoietic stem cell transplantation (HSCT) has evolved into an effective strategy for the 
treatment of certain hematological malignancies and inborn errors. Allogeneic transplantation 
involves the transfer of stem cells from donor to recipient, and as a consequence, an 
introduction of histoincompatible cells occurs. The degree of histoincompatibility influences 
the incidence of graft rejection and graft-versus-host disease (GvHD).1 
In addition to preventing the graft from immunological rejection, the patient has to be 
immunosuppressed at the time of stem cell transfer.2,3 A combination of chemotherapy and 
total body irradiation was the choice of treatment in the past; nowadays, powerful 
immunosuppressive drugs instead of, or in combination with irradiation are common practice. 
Under these circumstances stem cells derived from the transplant donor are required to 
rescue hematopoiesis.1 The immunosuppression has to be continued for 3-6 months, until 
the donor-derived immune system reconstitutes.2,3 The velocity of the immune reconstitution 
following HSCT depends on donor type, intensity of post-transplant immunosuppression and 
on the extent of T cell depletion in the graft.3 
As a result of immunosuppression, recipients are susceptible to a wide range of serious and 
often lethal opportunistic infections.1,2 Although bacterial infections are common, in general 
they can be controlled by the appropriate antibiotics. Viral infections are less well controlled 
and are the main clinical burdens nowadays.1,4 New infections play a subordinate role, more 
often the reactivation of latent viruses, such as Cytomegalovirus (CMV), Epstein-Barr virus 
(EBV) and Adenovirus (ADV) are common and cause symptomatic disease.4 For CMV and 
EBV, antiviral pharmacologic agents are cost intensive but eliminate the infection quite 
effectively. ADV-infection treatment of immunocompromised patients, on the other hand, is 
still unsatisfactory and less effective.5 
In the last years an increasing incidence of ADV-infections has been observed, attributed 
either to an improvement of diagnostic tools and a more widely spread screening or to an 
extension of stem cell transplantation to higher risk patients.2,3,6 
 
An unmanipulated hematopoietic stem cell (HSC) inoculum from the bone marrow contains a 
large number of T cells from the donor (1 x 109 - 5 x 109). The amount could increase to 5 x 
1010, if peripheral-blood HSC are used, through donor stimulation with granulocyte colony-
stimulating factor (G-CSF).  
Although donor T cell populations provide partial protection against infection, unfortunately, 
these cells are also responsible for the development of GvHD. To minimize this risk, T cell 
depletion is widely used for unmatched donor transplants, whereas the optimal T cell dose 
remains a hotly debated issue in the field of clinical transplantation.1 
1 Introduction 
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1.2 Adenovirus 
1.2.1 Biology of adenovirus 
Human ADV is a non-enveloped, ubiquitous, lytic double-stranded, up to 36kb DNA virus. 
More than 50 different human serotypes with varying tissue tropism have been identified and 
the number of new potential serotypes has increased in the last years. They are divided into 
6 subgroups (A-F) according to their oncogenic potential in rats, hemaglutinating properties, 
morphological and DNA sequence characteristics.3,7,8 
The morphology of ADV is characterized by an icosahedral protein capsid, comprising  three 
major proteins: hexon, penton base and a fiber (Figure 1).3,8 
 
Figure 1. Morphology and genome organization of adenovirus.  
(A) Adenovirus structure with the major structural components: fiber, hexon and penton, 
furthermore pIIIa and pIX stabilize the virus particle, inside a double-stranded DNA is located.8  
(B) The genome of about 36kb is divided into early (E1-4), intermediate (Iva2) and late (L1-5) 
genes, flanked by right and inverted terminal repeats (ITR). MLP: major late promoter.9 
 
1.2.2 Infection 
Transmission occurs through respiratory droplets or the fecal-oral route.3 Adenoviruses are 
endemic in all populations throughout the year, 80% of children between the ages of 1 and 5 
years have antibodies to one or more serotypes, which indicates a past or current ADV 
infection.6 
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ADV can infect nearly all human cells,3,10 although they persist preferably in epithelial cells 
and lymphoid tissue.7 Lion at al. suggest that the intestinal tract may be the primary site of 
ADV reactivation, at least in pediatric transplant recipients.7 
 
1.2.3 Diagnosis and clinical manifestation  
In the last years real-time PCR assays have evolved as a main diagnostic tool for detection 
and quantification of ADV in blood, stool, urine and throat.7 The wide range of serotypes with 
major genetic differences has become manageable by designing practical primer 
combinations from the hexon and the VA RNA region.11,12 
In general, human ADV is not considered to be highly pathogenic in immunocompetent 
individuals, apart from that, only half of the strains are associated with clinical symptoms.3,5 
Primary infection appears very often during infancy and in most cases it is and remains 
asymptomatic. Trivial gastrointestinal and respiratory symptoms can sometimes be 
observed,3 yet the diseases are typically mild and mostly resolve without sequelae. Only in 
rare cases, hepatitis, myocarditis, meningoencephalitis or nephritis are observed.5,7 
 
In patients with compromised immunity, however, ADV-infections are associated with a high 
incidence of morbidity and mortality, occurring in 20-30% after HSCT in pediatric patients, 
whereas only 3-13% of adults are affected.6 In patients with disseminated disease the 
mortality rate could be as high as 60%6 to 70%13.  
 
Detection and selection of virus-specific T cells by human leukocyte antigen (HLA)-
peptide pentamers 
The direct measurement of specific lymphocytes with the multimer technology was described 
the first time 1996 by Altman et al.14 This tool is based on the fact that T cells recognize 
peptides, derived from pathogens that are bound to major histocompatibility complex (MHC) 
molecules on the surface of target cells or antigen-presenting cells (APCs). This recognition 
is very specific and makes it possible to identify antigen-specific T cells by binding of MHC 
allele attached to fluorochrome (Figure 2).15 
 
However, most tools focus on the analysis of CD8+ T cells (MHC I), although new tools for 
the analysis of MHC-class-II-restricted T cell responses and CD1-restricted natural-killer T 
cell responses are being developed.15 
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Figure 2. Multimer technology.  
MHC class I (yellow) is conjugated via biotin (blue) to a fluorescently labeled straptavidin (red). 
This complex binds to peptide (violet) pulsed T cell receptor (TCR, blue), whereas CD8 (pink) 
support the complex binding. A schematic drawing of a tetramer (consisting of 4 equal MHC I-
peptide molecules) used for CMV staining is shown. For analysis of ADV, a pentamer (consisting 
of 5 equal MHC I-peptide molecules) was used to quantify ADV-specific T cells.15  
 
1.2.4 ADV-specific immunity 
Innate and adaptive immune systems respond to ADV infections, nevertheless, the long-term 
success rate after HSCT is mainly affected by the acquired immune mechanism.  
The frequency of antigen-specific T cells increases in response to an acute infection and 
normally declines after successful control of the virus. These results correlate with the 
findings in patients after HSCT, where T cell reconstitution is required for the control of ADV-
infections.3,6 Feuchtinger et al. have shown that the presence of ADV-specific T cells in post-
HSCT is associated with a favorable prognosis, whereas their absence could lead to ADV-
associated mortality.3 
 
In the presence of viral antigen and a high viral load in peripheral blood, virus-specific T cells 
undergo expansion in vivo and decline to normal values after successful elimination of ADV 
infection (HAdV DNA) (Figure 3A). For a lifelong protection memory T cells remain behind. In 
case of reactivation or reinfection, clonal expansion of effector cells from the memory pool is 
initiated and leads to an increased size of virus-specific T cell population. Furthermore, 
Feuchtinger et al observed the reconstitution of different cell phenotypes (Figure 3B) after 
HSCT: The recovery of T cells takes about 100 days and the T-HELPER cells reach normal 
values after 150 days. Natural killer cells (NK cells), which are part of the adaptive immune 
system, reach their maximum already 1-2 months after transplantation, T cell counts, on the 
other hand, are only completely normal after 1 year.3 
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The influence of T cell depletion on the T cell reconstitution is shown in Figure 4. T cell 
reconstitution correlates with the time needed for immunological tolerance between host and 
donor cells, which is normally established after one year at the latest. In contrast,  the 
transplantation of solid-organ allografts requires a lifelong immunosuppression treatment.1 
 
 
Figure 3. Immune reconstitution after T cell depleted stem cell transplantation. 
(A) During an ADV infection the correlation of the viral load (HADV DNA, blue) with the 
percentage of ADV-specific T cells (HAdV specific T cells, red) is shown. (B) Reconstitution of T 
cells (blue), T-HELPER cells (red), NK-cells (yellow) and circulating mature T cells (green) regarding 
the time after haploidentical stem cell transplantation (SCT). Arrow indicate the period, where 
patients are particularly susceptible to ADV infections.   
Original image:3, modified by Christine Freimüller.  
 
 
Figure 4. T cell immune reconstitution after allogeneic HSCT.   
a) After T cell depletion, T cells mature from the HSCs of the donor and are functionally 
competent but are fully tolerant of both host and donor tissue. This process takes at least 100 
days. b) Without T cell depletion mature T cells are present in the HSC graft, providing a cellular 
immunity, however bearing the risk to induce GvHD.1 
 
It is known that CMV and EBV infections are mainly excluded by CD8+ T cells.13 Instead, 
eradication of ADV is assumed to be mediated by CD4+ T cell response,6,16 although newer 
findings indicate the importance of CD8+ T cells.2,5 Leen at al. used a peptide library 
spanning the entire sequence of the hexon protein, to stimulate ADV-specific T cells. 
Thereby they discovered new HLA-dependent peptide-sequences for CD8 and CD4 positive 
T cells, which could be used for the production of multimers.17 Based on these findings, 
strategies for new treatments are considered. 
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Cytotoxic potential 
Virus-infected cells are recognized by immune cells with a strong cytolytic response. 
Immediately after activation, through MHC-mediated recognition of cognate peptide, cytotoxic 
CD8+ T lymphocytes produce cytokines and chemokines and mediate target cell 
elimination.18 Different surface markers for cytotoxic killing, such as CD107a, CD107b and 
CD63, were identified in recent years.18,19 These molecules are expressed on the surface 
immediately after cytotoxic granule release.18 
 
Cross reactivity over subtypes and species 
In general, human T cell recognition of epitopes is conserved between different but related 
subtypes of viruses, for ADV, however, this does not always apply.16 The T cell response is 
mainly directed against the hexon protein, which is located at the capsid protein. The amino 
acid sequence of the hexon protein varies between species and subtypes whereas variable 
and conserved regions were identified.3 Since these epitopes are largely conserved, specific 
T cells were shown to be cross-reactive towards ADV serotypes from different ADV 
subgroups, and may therefore provide protection against a wide range of ADV serotypes, 
albeit with a few exceptions.20 
 
Differentiation of T cells and their ability to remember 
“The adaptive immune system has evolved a unique capacity to remember a pathogen 
through the generation of memory T cells, which rapidly protect the host in the event of 
reinfection.”21 
We focused on central memory T cells (TCM), which could provide long-lived protection from 
viral disease after HSCT. 
 
Over the past years, it has become evident that the first contact of a naïve T cells with the 
priming antigen does not turn irrevocably into memory or effector cells, they can convert into 
nearly all different subtypes during their lifespan.  
If an infection is entirely cleared a small fraction of long-lived memory cells (Figure 5) can 
persist in the absence of further antigen stimulation. These populations comprise only 5-10% 
of the initial burst size.22 These cells have generally been described as specialized cells with 
the ability to reactivate effector functions in a short time period and expand huge populations 
of them.23 
Central memory cells have also been identified by high basal and cytokine-induced STAT5 
phosphorylation, reflecting their capacity for slow but constant self-renewal (Figure 5).22,24 
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Figure 5. Differentiation capacity of naïve and memory CD8+ T cells. 
Priming of a single naïve antigen-specific CD8+ T cell initiates the differentiation into effector T 
cell (TEC, Teff), effector memory T cells (TEM) and central memory T cell (TCM). A few TCM 
cells develop a “stem cell-like” differentiation capacity like naïve CD8+ T cells.22 
 
The different phenotypes of T cells are characterized by the expression of several surface 
markers, which can be down or up-regulated during their lifespan. Lymph node homing 
receptors CD62L and CCR7 (L-selectin) are only expressed on naïve T cells, which have not 
been exposed to antigens, and on central memory T cells, which can return for a secondary 
clonal expansion.25 
Furthermore, CD45 (Protein tyrosine phosphatase, receptor type C ; PTPRC) was selected 
to distinguish between naive T Tells, expressing the large isoform of CD45 (CD45RA) and 
activated and memory T cells, showing CD45RO on their surface.26,27 
Taken together, T cell populations could be separated by their surface marker expression 
into four distinct sub-populations (Table 1). However, in humans the developmental 
relationship among TCM, Teff, and Temra is still controversial, Stemberger et al. illustrate an 
overview of the common findings (Figure 5). 
 
Table 1. T cell populations and there surface marker expression. 
 
 CD45RA CD62L 
TCM (central memory T cell) - + 
Temra (effector memory RA+ T cell) + - 
Teff (effector T cell) - - 
naïve T cell + + 
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The isolation of the “right” T cell subset would decrease the required large number of in vitro-
expanded effector T cells, as is currently common for adoptive immunotherapy. If less-
differentiated antigen-specific T cells can be isolated and their fate, either to differentiate into 
an effector or a memory cell can be influenced, only very low numbers of adoptively 
transferred T cells are necessary.23 
 
The process of T cell maturation is continuously shaped by the surrounding environment, 
whereas cytokines play an important role in vitro and in vivo. 
Williams et al. suggest that the presence or absence of Interleukin-2 (IL) signaling 
determines whether T cells become differentiated effector or memory cells.28 Further on 
Pipkin et al. confirmed that the transcriptional program for inflammation after infection is 
induced by IL-2 signaling and so ensures a balance of effector and memory T cell 
differentiation.29 Stemberger et al. noted that IL-15 is more likely to promote homeostatic 
proliferation and IL-7 signals are mainly needed for survival.22 Weninger et al. showed the 
dose-effect of IL-2: if cells were cultured in the presence of ≥5ng/ml IL-2, they developed the 
phenotype and function of effector T cells. In contrast, ≤5ng/ml IL-2 mediated rapid recall 
responses - when transferred into naïve animals - which represents a memory type. IL-15 
administration turns antigen-primed CD8+ T cells into central memory T cells.30 
Most reports, however, focus on the observation of CD8+ T cells, but with the addition that 
CD4+ T cells show similar characteristics.24,30 
 
1.2.5 Treatment 
Interestingly there is no formally approved effective anti-adenoviral agent available.5,10 
Ribavirin, cidofovir, ganciclovir, vidarabine and ddC are the most widely used antiviral 
agents, however, their efficacy to provide protection against the adenovirus is limited and 
associated with significant side effects.3,5,10,17,31 Furthermore, there is the risk of 
overtreatment on a large scale if the administration of antiviral drugs in all patients with ADV 
detectable in stool is to be implemented.7 
 
One approach to prevent and treat the viral infection is the administration of donor-leukocyte 
infusion (DLI), which consists of unmanipulated T cells isolated from the stem cell donor 
(Figure 6B).2 Witt et al. published a case report, where a HSCT-treated 2-year old patient 
was cured of CMV infection after irradiated leukocyte transfusion therapy from a CMV 
seropositive donor. By that time, CMV-specific T cell analysis was not established, yet Witt et 
al. assumed that the T cells infused together with the irradiated leukocytes played a decisive 
role.32 The mechanism of DLI is not completely understood, but there might be a switch in 
chimerism of antigen-presenting cells (APCs) from host to donor. In general, this approach is 
associated with an increase in the incidence and severity of acute GvHD.1 Nevertheless, this 
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kind of treatment has long been a favored therapy – not least because there were no better 
therapy options available so far. 
 
It is now assumed that the degree of immune reconstitution and the resulting efficiency of 
virus-elimination is mainly influenced by the frequency of virus-specific T cells. Therefore, 
adoptive transfer of virus-specific T cells from matched or even haploidentical allogeneic 
donors into patients, was shown to cure viral infections (Figure 6C).1,2 Pure ADV-specific T 
cells can be delivered without any concern about generating alloreactive immunity. The 
transfer will, however, only be successful, if the donor has immunity to the relevant 
pathogen.1 There are some promising results for CMV and EBV infections in 
immunocompromised patients.4,5 
For ADV several approaches were published in the last years, whereas large-scale clinical 
applications are still missing. Chatziandreou et al., for example, published a potential 
method: they isolated interferon-gamma (INF-γ) secreting ADV-specific T cells.13 Feuchtinger 
et al. reported the induction of an effective and specific T cell response after the infusion of 
ADV-specific T cells (CD4+ and CD8+) into pediatric patients undergoing HSCT.5,33 Leen et 
al. produced bivirus- (EBV, ADV) and trivirus- (EBV, ADV, CMV) specific T cell lines, through 
the use of chimeric adenoviral vectors, with a proven record of success.34,35  
The disadvantages of these tools are the labor-intensive techniques and the resulting high 
costs, otherwise the specific administration increases the survival rate and reduces the 
undesired side effects of antiviral drugs.1 
 
Figure 6. Evolution of adaptive T cell therapy for viral infections after allogeneic HSCT. 
(A) Hematopoietic stem cell inoculum (B) Donor-leukocyte infusion (C) Virus-specific T cells 
isolated and clonally expanded in vitro before adoptive transfer to the host.1 
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1.3 Aims of research 
ADV-infection after HSCT is a serious complication, with a high risk of morbidity and 
mortality, especially in children. Treatment options have remained unsatisfactory, only 
occasionally adoptive T cell therapy has yielded promising results. In terms of reliability as 
well as regarding the costs, the application of adenovirus HLA-multimers simplifies the 
analysis of ADV-specific T cells. 
Based on these findings, two main aims for the study were determined: 
 
(1) Expansion and characterization of in vitro-generated ADV-specific T cells. 
The first aim was to increase the yield of ADV-specific T cells and to shorten the required 
expansion time. Therefore optimal cell culture conditions and the influence of several 
cytokines such as IL-2, IL-7 and IL-15, were approved. 
Furthermore, the distribution of effector memory versus central memory cells during the 
expansion process was studied. In addition the functional activity and alloreactivity of 
expanded cells were analyzed. 
 
(2) Irradiated virus-specific T cells as therapy after allogeneic hematopoietic stem cell 
transplantation.  
The second aim was to completely exclude the alloreactivity of expanded T cells without 
influencing their functional activity. Irradiation of T cells is a commonly used method to 
impede cell proliferation, resulting in induced apoptosis in T cells after several days. However 
the functional activity of irradiated cells before going into apoptosis was never tested so far. 
Therefore we analyzed the influence of irradiation, on the functional activity of expanded T 
cells.   
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2 Materials and Methods 
2.1 Materials 
2.1.1 Apparatuses and Instruments 
Cell counter (Sysmex Europe, Norderstedt, Germany)  
Cell incubator (Heraeus, Newport Pagnell, UK) 
Centrifuges with applications for plates and tubes (Heraeus, Newport Pagnell, UK)   
Fluorescence-activated cell sorter (FACS AriaTM, BD, San Jose, CA, USA) 
Freezers (-20° C, -80° C, Nitrogen) 
Fridges 
Laminar flow (Esco, Hatboro, PA, USA) 
LSR II flow cytometer (BD, San Jose, CA, USA) 
MACS® Seperation Colums: MS, LS (Miltenyi Biotec, Bergisch Gladbach, Germany) 
Mini/MidiMACSTM Separator (Miltenyi Biotec, Bergisch Gladbach, Germany) 
Octo/QuadroMACSTM Separator (Miltenyi Biotec, Bergisch Gladbach, Germany) 
Optical microscope, Nikon TMS (Nikon Corporation, Tokyo, Japan) 
Pipette (Gilson, Middelton, WI, USA) 
Radiation apparatus: IBL 437 C (CIS BIO International, Bagnols, France) 
Rotator (MACS Mix, Miltenyi Biotec, Bergisch Gladbach, Germany) 
SPHEROTM Ultra Rainbow fluorescent particles (Sperotech, Libertyville, US) 
Vortex Genie 2 (Lactan, Graz, Austria) 
 
FACSDiVaTM software (Version 6.1.2, BD, San Jose, CA, USA) 
GraphPad Prism 5 Software (GraphPad, San Diego, CA, USA) 
 
2.1.2 Plastic Material 
Tissue culture plate, 96-well, round bottom (NuncTM, Roskilde, Denmark)  
Tissue culture plate, 6-well, 12-well, 24-well, 48-well (IWAKI Europe, Willich, Germany) 
FACS tubes (Polystyrene round-bottom tube, B, San Jose, CA, USA) 
TruCOUNTTM Tubes (BD, San Jose, CA, USA) 
Filter tubes (Polystyrene round-bottom tube with cell-strainer cap, BD, San Jose, CA, USA) 
CryoTube vials (NuncTM, Roskilde, Denmark) 
Cell scraper (PAA, Pasching, Austria) 
Tissue culture flasks, 25cm2, 75cm2 (IWAKI Europe, Willich, Germany) 
Sterile tips, 10, 20, 100, 200, 1000µl (MβP, San Diego, USA) 
Tubes with lid, 15, 50ml (BD, San Jose, CA, USA) 
Pipettes, 1, 2, 5, 10, 25ml (SPL Lifesciences, Gyeonggi-do, Korea) 
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2.1.3 Chemicals and Regents 
Human serum type AB, AB-Serum (PAA, Pasching, Austria) 
AIM-V® medium (Invitrogen, Lofer, Austria) 
Antibodies (2.1.7) 
Aqua bidestillata (Mayrhofer, Leonding, Austria) 
Bovine serum albumin, BSA (Sigma-Aldrich, St Louis, MO, USA) 
CFSE 1mM (Sigma-Aldrich, St Louis, MO, USA) 
CliniMACS® PBS/EDTA (Miltenyi Biotec, Bergisch Gladbach, Germany) 
Dimethylsulfoxid, DMSO (CryoSuve, Impfstoffwerk Desau-Tornau, Germany) 
Ficoll: LSM 1077 Lymphocyte (PAA, Pasching, Austria) 
Hepes buffer 1M (Invitrogen, Lofer, Austria) 
Human serum albumin, HSA (Octapharma, Wien, Austria) 
L-Glutamine (PAA, Pasching, Austria) 
Natriumacid 10% (produced by Triimed, Wien, Austria) 
Octaplas® AB (Octapharma, Wien, Austria) 
Phytohaemagglutinin (PHA, Sigma Aldrich, Austria) 
Phosphate-buffered saline, PBS(1x) (PAA, Pasching, Austria) 
RPMI 1640, with or without L-Glutamine (PAA, Pasching, Austria) 
 
2.1.4 Buffer and Media 
AIM-V+++ 
AIM-V®  supplemented with:    2% Octaplas® AB 
       1% L-Glutamine 
       1M Hepes buffer 
 
CFSE label buffer 
PBS(1x) supplemented with:    0.1% BSA 
 
Freezing medium      20% DMSO 
       39% Octaplas® AB 
       41% AIM-V®    
    
MACS buffer CSA 
CliniMACS® PBS/EDTA supplemented with:  2.5% Human serum type AB 
 
MACS buffer 
CliniMACS® PBS/EDTA (Miltenyi) 
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Monocyte adherence buffer 
AIM-V® supplemented with:    1% Octaplas® AB 
 
Secretion medium CSA 
RPMI 1640 supplemented with:   1% L-Glutamine 
       5% Human serum type AB 
 
Washbuffer ADV 
PBS (1x) supplemented with:    0.1% BSA  
       0.1% Natriumacid 
 
2.1.5 Stimulants reagents 
All reagents were dissolved and diluted according to manufacturers´ instructions. 
 
2.1.5.1 Adenovirus 
PepTivator ADV  
PepTivator-AdV5 Hexon consisting of 15mer sequences with 11 amino acid overlap covering 
all the hexon protein from ADV type 5 (Miltenyi Biotec). Used concentration: 0.5µg/ml.  
 
Peptide ADV 
Customized proteins of ADV2 Hexon produced by IBA (Göttingen, Germany). 
HLA-A*0101  LTDLGQNLLY 
HLA-A*0201  LLDQLIEEV   
HLA-A*2401  LLDQLIEEN 
HLA-B*0702  KPYSGTAYNAL 
HLA-B*3501  MPNRPNYIAF 
Used concentration: 2µg/ml. 
 
2.1.5.2 Staphylococcal enterotoxin B (SEB) 
SEB stimulates unspecific immune response (Sigma-Aldrich, St Louis, MO, USA). Used 
concentration: 0.1mg/ml. 
 
2.1.5.3 Phytohaemagglutinin (PHA) 
PHA triggers cell division into immature T-lymphocytes. Used concentration: 2.5µl/ml. 
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2.1.6 Cytokine 
All reagents were dissolved and diluted according to manufacturer´s instructions. 
 Concentration Source 
IL-2 5ng/ml PeptroTech, NY, USA 
IL-7 5ng/ml R&D Systems, Minneapolis, MN, USA 
IL-15 5ng/ml R&D Systems, Minneapolis, MN, USA 
 
2.1.7 Antibodies  
AB specifity Conjugate Clone Used volume (µl) /2.5 x 105 cells Source 
CD3 Pe-TR UCHT1 1# BD Bioscience* 
CD3 PerCP SK7 4 BD Bioscience* 
CD3 PE UCHT1 2# DAKO**** 
CD4 PerCP-eFlour® 710 SK3 2 eBioscience** 
CD4 PE-Cy7 SK3 3# BD Bioscience* 
CD8 V500 RPA-T8 2 BD Bioscience* 
CD8 APC-Cy7 SK1 4# BD Bioscience* 
CD8 PerCP SK1 8# BD Bioscience* 
CD19 APC-Cy7 SJ25C1 1 BD Bioscience* 
CD20 APC-Cy7 L27 1 BD Bioscience* 
CD27 PE-CyTM7 M-T271 1.5 BD Bioscience* 
CD45RA PE-TR HI100 0.01 BD Bioscience* 
CD57 FITC HNK-1 2 BD Bioscience* 
CD62L BD Horizon™ V450 DREG-56 0.5 BD Bioscience* 
CD107 FITC H4A3 4# BD Bioscience* 
CD137 PE 1HA2 4# BD Bioscience* 
CCR7 Alexa Fluor® 647 TG8/CCR7 5 BioLegend*** 
     
isotype     
 Alexa Fluor® 647  MOPC-173 5 BioLegend*** 
 
 
#
 for 106 cells 
* BD Bioscience, San Jose, CA, USA 
** eBioscience, San Diego, CA, USA 
*** BioLegend, San Diego, CA, USA 
**** Dako, Glostrup, Denmark 
 
2.1.8 Viability staining 
DAPI (4',6-diamidino-2-phenylindole) (Invitrogen, Lofer, Austria), 16.5µl/ml 
Syto41 (Invitrogen, Lofer, Austria), 3-4µl/ml from 1:200 dilution 
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2.1.9 ADV pentamere 
All reagents were dissolved and diluted according to manufacturers´ instructions. 
Pro5® MHC class I pentamer (ProImmune, Oxford, UK): 
HLA-Type Sequence Epitope origin Conjugate 
A*0101 TDLGQNLLY Adenovirus 5 Hexon 886-894 PE 
A*2402 TYFSLNNKF Adenovirus 5 Hexon 37-45 PE 
B*0702 KPYSGTAYNAL Adenovirus Hexon 114-124 PE 
B*3501 MPNRPNYIAF  PE 
 
2.1.10 Further equipment  
Cytokine secretion assay kit 
 Conjugate Used volume# Source 
INF-y Catch 
Reagent 
to cell surface (CD45)  
specific monoclonal antibody 10µl Miltenyi Biotec* 
INF-y Detection 
Antibody APC 10µl Miltenyi Biotec* 
 
 
# for 106 cells 
* Miltenyi Biotec, Bergisch Gladbach, Germany 
 
Magnetic cell sorting: Isolation of CD14+ cells 
CD14 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) 
 
2.1.11 Patient samples 
Blood samples (heparin or EDTA – ethylenediaminetetraacetic acid) were obtained from 
healthy donors at the Children´s Cancer Research Institute (CCRI) with their full knowledge 
and permission. 
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2.2 Methods  
All cell culture work was performed under sterile conditions. 
A washing step describes the following procedure: adding washing solution, centrifugation at 
300g, 4°C for 10min and removing the supernatant.  
 
2.2.1 Generation of virus-specific T cells 
2.2.1.1 Isolation of peripheral blood mononuclear cells (PBMCs) 
PBMCs were obtained from whole blood of informed healthy volunteers by density gradient 
centrifugation using ficoll (LSM 1077 Lymphocyte). Whole blood supplemented with EDTA or 
Heparin was diluted 1+1 to 1+2 with room temperature (RT) PBS. For density gradient 
centrifugation a layer of diluted blood was pipetted onto 3-15ml of ficoll and was spun for 
30min at 1000g without brake. The mononuclear cell layer, which formed a ring in the 
interphase, was carefully transferred into a new tube and washed twice with cold PBS or 
RPMI. After the first washing step, cells were resuspended in a defined volume and 65µl 
were removed for the determination of the cell number by Sysmex.  
 
2.2.1.2 Freezing and Thawing 
Mammalian cells can be stored in liquid nitrogen for a long time or for shorter periods at -
80°C with minimal loss of viability. For this application, cells were counted and resuspended 
in cell culture medium AIM-V+++. This suspension was transferred into CryoTube vials and 
charged with freezing media in a ratio of 1:1. Samples were cooled down at -80°C, and if the 
cells were intended to be stored for a longer period, they were put into liquid nitrogen after 
one day.  
 
For thawing, frozen cells were warmed up with pipetting up and down cold PBS or RPMI. The 
cell suspension was transferred into a new tube and washed twice to remove DMSO. Cell 
number was determined after the first washing step. After the second washing the pellet was 
resuspended in cell culture medium. 
 
2.2.1.3 Cell culture 
Cells were cultured in AIM-V® medium supplemented with 2% octaplas, 1% L-glutamine and 
1M hepesbuffer. Cultivation took place at 37°C supplied with 5% CO2 and 90% relative 
humidity in an incubator. 
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2.2.1.4 Expansion of ADV-specific T cells (in vitro cell stimulation) 
Depending on the aim of the experiment 6, 12, 24, 48 well-plates or 25, 75cm2 flasks were 
used. Isolated PBMCs were seeded at a density of 5 x 106/ml (Table 2). 
For ADV cell stimulation PBMCs were incubated with 1µg/ml (20µl/ml) PepTivator ADV or 
2µg/ml (2µl/ml) peptide ADV.  
After three days 5ng/ml IL-15 was added.  
On day 6 expanded cell culture was restimulated: for this purpose, monocytes were isolated 
from PBMC by means of monocyte adherence. Frozen PBMCs were thawed like described 
above, resuspended in AIM-V® supplemented with 1% octaplas® AB, and seeded at the 
same density as on day 0. After 2h monocytes had settled down on the bottom of the flask or 
plate. To remove unwanted non adherent cells, cells were washed shortly with PBS. In the 
meantime the expanded ADV-specific T cells were scraped from the flask or plate and 
washed once with PBS or RPMI. The pellet was resuspended in the same volume of AIM-
V+++ as before the washing step. Washed ADV-specific cell culture was given to the 
adherent monocytes and was treated with PepTivator ADV or Peptide ADV, like on day 0. 
On day 9 the cell culture was enriched with 5ng/µl IL-15. After further 3 days, expansion of 
ADV-specific T cells was completed (Figure 7). 
 
 
Figure 7. Expansion of ADV-specific T cells. 
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Table 2. Plate size and absolute cell count. 
 
 
 
 
 
 
 
 
2.2.2 Irradiation 
The irradiation treatment of cell culture was accomplished with the IBL 437 C (CIS BIO 
International, Bagnols, France) at the AKH Wien, Transfusionsmedizin. Cells were irradiated 
with 30Gy (3000rad), which corresponds to the typical irradiation procedure of blood 
products. 
 
2.2.3 Detection of circulating virus-specific T cells  
2.2.3.1 Column-based isolation of antigen-specific cells 
Magnetic cell sorting (MACS) is a method for selective enrichment or depletion of cells, 
expressing a surface marker characteristic for their cell type. Cells can be primary labeled 
with magnetic antibodies, which are retained in the column, unlabeled cells, on the other 
hand, pass through. 
 
Pre-cooled solutions were used and cells were kept on ice, unless otherwise mentioned. All 
used volumes of reagents were calculated for 107 cells, when more cells were loaded on the 
column, the amount was increased in relation to the cell count. 
 
2.2.3.1.1 Isolation of CD14+ cells (monocytes) 
Monocytes were positively selected by MACS using the human CD14 MicroBeads (Miltenyi 
Biotec). 
Frozen PBMCs were thawed and washed once with PBS at 300g, 10min, 4°C and 1 x 107 
cells were resuspended in 80µl of MACS buffer. 20µl CD14 magnetic beads were added and 
incubated for 15min at 4°C in the dark. Cells were washed by adding 2ml MACS buffer and 
resuspended up to 108 cells in 500µl of MACS buffer. MS column (Miltenyi Biotec) was 
placed in the magnetic field of the MACS separator and equilibrated with 500µl ml MACS 
buffer. The sample was applied onto the column and washed three times with 500µl MACS 
buffer. After removing the column from the separator, the labeled CD14+ cell fraction was 
 Absolute cell count Volume 
6-well plate 10 x 106 2ml 
12-well plate 5 x 106 1ml 
24-well plate 2.5 x 106 0.5ml 
48-well plate 1.25 x 106 0.25ml 
96-well plate 0,625 x 106 0.125ml 
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flushed out with 1ml MACS buffer by pushing the plunger into the column. The monocyte-
containing fraction was washed twice with PBS and was resuspended in the volume of 
choice for the further use at the cytokine secretion assay (2.2.3.3 Cytokine secretion assay 
(CSA)).  
 
2.2.3.1.2 Isolation of ADV-specific T cells 
Following ProImmune protocol “Column-based isolation of antigen-specific cells using anti-
fluorochrome beads”, 30 - 40 x 106 expanded cells were used for each approach. The 
following description is designed for 106 cells. 
Cells were washed once with 1ml washbuffer ADV and resuspended in 50µl washbuffer. For 
20min, at RT, 5µl corresponding PE labeled pentamer was added. After washing, cells were 
resuspended in 80µl washbuffer ADV and 20µl anti-PE magnetic beads (Miltenyi Biotec) 
were added for 15min at 4°C. Cell-bead complex was washed once and resuspended in 
500µl washbuffer. LS column was prepared as described in the company´s instruction 
(Miltenyi Biotec) and loaded with the cell-bead complex. For collecting the negative fraction, 
3 times 3ml washbuffer ADV were added. Afterwards, the column was replaced from the 
magnetic field and the ADV-specific T cells (positive fraction) were eluted with 5ml 
washbuffer ADV through pushing the plunger into the column.  
The positive fraction was washed and all cells were stained as described in “2.2.3.4 
Phenotype analysis”. 
 
2.2.3.2 Pentamer staining 
For each staining condition 2.5 x 105 cells were used.  
Cells were washed once with 1ml washbuffer ADV (0.1% BSA, 0.1% Natriumacid in PBS) 
and resuspended in 50µl washbuffer ADV. Afterwards cells were incubated with the 
corresponding pentamer labeled to PE for 20 min, dark, at RT. The used amount of the 
pentamer is listed in Table 3. Another washing step was done and further surface markers 
were stained as described in “2.2.3.4 Phenotype analysis”. 
 
Table 3. Pentamer staining for ADV. 
 
 
 
 
 
 
 
ADV Pentamer Used volume 
positive  corresponding pentamer  (A*0101, A*2402, B*0702, B*3501) 5µl / 2 x 5*10
5
 cells 
negative non corresponding pentamer  (A*0101, A*2402, B*0702, B*3501) 5µl / 2 x 5*10
5
 cells 
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2.2.3.3 Cytokine secretion assay (CSA) 
This assay is designed for the quantification of live antigen-stimulated INF-γ secreting CD4+ 
and CD8+ memory and effector T cells (Figure 8). 
The assay was carried out with the cytokine secretion assay kit (Miltenyi Biotec) according to 
the manufacturer´s instructions.  
 
Expanded ADV-specific T cells were washed, counted and adjusted: 50µl = 8 x 105 cells. 
Half of the cells were irradiated, the others served as control. 
Monocytes were positively selected by using CD14 MicroBeads (Miltenyi Biotec) as 
described in 2.2.3.1.1 Isolation of CD14+ cells (monocytes). Selected cells were counted and 
adjusted: 50µl = 2 x 105 cells. 
Monocytes and expanded T cells, either irradiated or not, were mixed in a rati of 5:1, 
(50µl+50µl). Stimulation was performed for 16h or 4h, with either 0.5µg PepTivator ADV, 
10µg SEB or, for the negative control, without stimulant.  
After the stimulation period cells were washed with 10ml washbuffer MACS CSA (MACS 
buffer with 0.5% HSA) and resuspended in 80µl cold secretion medium (RPMI 1640 with 1% 
L-Glutamine and 5% AB-serum). 10µl INF-y catch reagent were added and incubated for 
5min on ice, then 5ml 37°C warm secretion medium were added and under rotation INF-y 
were secreted for 45min, at 37°C. Subsequently, cells were washed with washbuffer CSA 
and resuspended in 80ml cold washbuffer CSA. 10µl detection–antibody conjugated to APC 
and following antibodies were added for 20min, dark and on ice: CD3-PeTR, CD4-PeCy7, 
CD8-APC-Cy7, or CD3-Pe, CD4-PeCy7, CD8-PerCP and in a few cases CD137-PE and/or 
CD107a-FITC. Cells were washed again with 10ml washbuffer CSA, resuspended in 150µl 
washbuffer CSA and 3-4µl Syto41 was adjoined.  
 
 
 
Figure 8. Principle of the INF-γ secretion assay  
(A) Via stimulation - T cells get activated. (B) An INF-γ specific Catch Reagent is attached to the 
cell surface of all leukocytes through CD45 binding. (C) Cells are incubated for 45min at 37°C to 
allow cytokine secretion. The secreted INF-γ binds to the INF-γ Catch Reagent of the producing 
cells. (D) An INF-γ detection antibody conjugated to APC is used to visualize the secreting cells 
by flow cytometry. (INF-γ Secretion Assay- Detection Kit (APC), datasheet Miltenyi Biotec) 
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2.2.3.4 Phenotype analysis 
The washed cell pellet was resuspended in 50µl washbuffer ADV and supplemented with the 
following surface antibodies: CD3 – PerCP, CD4 – PerCP eFlour710, CD8 – V500, CD19 – 
APC-Cy7, CD20 – APC-Cy7, CD2 – Pe-Cy7, CD45RA – PeTR, CD57 – FITC, CD62L – 
Horizon and CCR7 – Alexa Flour 647. Labeling was performed for 15min at 4°C under dark 
conditions. Cells were washed once with washbuffer ADV, the pellet was resuspended in 
100µl PBS, stored cold and dark until  measurement.  
Control samples were stained with appropriate isotype-matched antibodies.  
 
2.2.4 Cytotoxic assay (CTA) 
2.2.4.1.1 Autolog system  
2.2.4.1.2 Target cell population 
PHA blasts and the target cells were generated from 3 x 106/ml PBMCs by adding 2mg/ml 
PHA on day 0. After 3 days 5ng/ml IL-2 was added and - when necessary - further cell 
culture medium was added.  
 
CFSE labeling 
After 6 days PHA blast were carboxyfluorescein diacetate (CFSE) labeled over night to 
distinguish between target and effector cells at the assay. 
PHA blasts were washed twice with PBS and the cells were resuspended in 0.1% BSA in 
PBS at a cell density of 107/ml. For CFSE staining, 3nM CFSE were added and incubated for 
10min at 37°C, for a good dispersion the cell culture was gently shacken every 2 minutes. 
For stopping the reaction, 1ml octaplas was added at room temperature for 5 minutes. Cells 
were washed one time with cell culture medium, a cell density of 1 – 2 x 106  was suspended 
and cultured over night. 
Cells were sorted for their viability using FACS AriaTM. 
For the pulsing procedure, 5 x 106/ml target cells were stimulated for 2h with 1µg/ml 
PepTivator or 2 µg/ml peptide ADV at a 96er well plate (round bottom). Additionally, cells 
were washed once and 50µl = 12.500 cells (2.5 x 105/ml) were adjusted. Unpulsed targets 
cells were treated in the same way but without simulation. 
 
2.2.4.1.3 Effector cell population 
Over 12 days expanded ADV-specific T cells were used as effectors, either irradiated or not. 
Viable cells were sorted by FACS AriaTM, washed once and a cell density of 5 x 106/ml 
(50µl=250.000 cells) was adjusted.  
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Figure 9. Schematic illustration of Cytotoxic Assay (CTA). 
Part of the expanded ADV-specific T cells (effector) were irradiated and after 6, 24 and 48h the 
assay was performed. A viability sort was performed before incubation for target and effector 
cells. PHA blasts, which function as target cells, were pulsed for 2h with either peptide or 
PepTivator ADV (not shown), afterwards effector and targets were mixed together in a ratio of 
20:1 and IL-15 were added. After 4h incubation the value of death target cells was evaluated by 
flow cytometry. 
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2.2.4.1.4 Assay 
An illustration of the CTA is shown in Figure 9. Target cells were placed in 96-well round–
bottom plates at 1.25 x 104cells/well. Effector cells were added at effector-to-target cell ratio 
of 20:1 in duplicates or triplicates. To determine the background, target cells were plated 
alone. Additionally, every well was filled up with cell culture medium to 200µl, further 1ng IL-
15 was added. Plate was centrifuged at 1200rpm for 10min at 4°C without brake and 
subsequently incubated for 4h.  
Cells were transferred into TruCOUNTTM tubes, 3.3µl DAPI were added and the value of 
death target cells was determined by LSRII. The amount of dead target cells is calculated in 
death target cells/µl.  
 
2.2.4.2 Allogeneic system 
ADV-specific T cell cytotoxicity was evaluated against autologous and allogeneic PHA blast 
target populations. Therefore non-irradiated or irradiated effector T cell population were 
incubated with the appropriate target cells. CTA was performed under the same conditions 
as described above.  
 
2.2.5 Flow cytometry 
2.2.5.1 Cytometric cell sorting  
For comparable results, the value of viable cells plays an important role. 
To achieve this, effector cells were sorted before the incubation and target cells were sorted 
before pulsing with an ADV stimulant. Cells were washed once with PBS, resuspended in 
0.5-3ml cell culture medium and filtered through a tube with cell-strainer cap. Viable cells 
were determined by the forward side scatter area (FSC-A) and side scatter area (SSC-A) and 
sorted in a separate tube by FACS AriaTM cytometer. After the procedure, cells were washed 
once with cell culture medium and the used cell density was determined. 
 
2.2.5.2 Flow cytometric analysis 
Single cell staining, a non-stained and a full stained sample were performed to determine the 
perfect compensation between different fluorochromes.  
The LSRII cytometer was equipped with three lasers (solid state lasers 405nm and 488nm, 
He-Ne laser 635nm). The cytometer performance is checked weekly using SPHEROTM Ultra 
Rainbow fluorescent particles (8-peak-beads; Sperotech, Libertyville, US). 
 
For a precise analysis, cells were transferred into TruCOUNTTM tubes (BD) where the 
absolute counts of leucocytes were determined with the following formula: 
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# of events in region containing cell x # of beads per test* = absolute count 
of cell # of events in absolute count bead region test volume 
 
*This value is found on the package and varies from lot to lot (BD TruCOUNTTM Tubes datasheet) 
 
For leukocytes, an acquisition threshold of 500 was set on FSC. Between 20.000 (CTA) and 
100.000 total events and a minimum of 1.000 beads were acquired per analysis.  
 
2.2.5.3 Data evaluation and gating strategy 
The BD FACS DiVaTM software was used for data evaluation. 
Depending on the used antibodies, different gating strategies were used, the following steps 
were always the same: First the beads were defined and then this gate was inverted to 
continue with everything without beads. For discrimination of doublets, cells were gated on 
SSC-area (SSC-A) versus FSC-width (FSC-W).  
 
For pentamer staining, CD19 and CD20+ cells were excluded, because they could provide a 
false-positive result for pentamer-positive cells. Further CD3+ cells were gated, dead cells 
were excluded by FSC-A versus SSC-A and splited in their surface expression of CD4 and 
CD8. The used pentamers are only able to recognize MHC Class I, therefore only virus-
specific CD8+ T cells could be detected with this analysis. CD8+ cells were analyzed in a plot 
PE versus SSC-A to distinguish between virus-specific T cells (pentamer+) and non-virus-
specific T cells (pentamer-). For the memory status CD62L and CD45RA provided important 
evidence, CCR7, CD57 and CD27 were stained but not appropriated for the results. 
 
For the cytokine secretion assay, first only viable cells have been gated by staining with the 
dye Syto41. Afterwards, CD3+ population was gated, accordingly CD4+ and CD8+ cells were 
determined. From both cell populations CD107, CD137 and INF-γ production was analyzed 
depending on their stimulation duration. 
 
For CTA analysis, CFSE positive cells, which comply with target cells, were gated and 
separated according to  their viability status by differentiating between DAPI+ (dead cells) 
and DAPI- (viable cells).  
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2.2.6 Statistics 
Data are presented in means ± SEM. 
Statistical analysis was conducted using GraphPad Prism 5 and Microsoft Office Excel 2007. 
A Student´s t test was used to compare two analyzed groups and significance considered 
when P was less than 0.05. 
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3 Results  
Only donors positive for ADV-specific T cells were eligible for this study.   
In all experiments, the unspecific binding of ADV-specific pentamer to CD8+ T cells 
(background level) was below 0.1%. 
 
3.1 Expansion and characterization of in vitro-generated ADV-specific T 
cells 
3.1.1 Expansion of ADV-specific T cells 
The presence of ADV-specific T cells in patients after HSCT was associated with clearance 
of viral infections. Therefore, the detection of ADV-specific T cells in HSCT donors and/or 
patients after HSCT could have implications for the onset of clinical symptoms of 
disseminated viral diseases. Since the frequency of ADV-specific T cells in fresh blood is 
very low, we developed an in vitro expansion period to be able to clearly detect and generate 
ADV-specific T cells. PBMCs of healthy donors were stimulated with an ADV-specific peptide 
pool (ADV-PepTivator) on day 0 and restimulated with autologous monocytes on day 6. On 
day 3 and 9, IL-15 was added to the culture. After 12 days cells were analyzed by flow 
cytometry using HLA-type pentamers or the IFN-γ CSA.  
As shown in Figure 10A, the frequency of ADV-specific T cells in freshly isolated PBMCs at 
day 0 is similar to that of cells stained with the unmatched HLA-type pentamer (negative 
control) and therefore below the limit of detection.  
However, after 12 days of expansion, a 1-2 log increase of pentamer positive ADV-specific T 
cells was observed, independent of whether cells/µl (Figure 10B and C) or the percentage of 
ADV-specific T cells in CD8+ T cells (Figure 10D and E) were analyzed. The ratios of ADV-
specific T cells on day 12 between different donors vary from 3.5 to 198 cells/µl (Figure 10B 
and C) and 1.9 to 43% of ADV-specific T cells in CD8+ T cells (Figure 10D and E). 
Since ADV viremia could disseminate within one or two weeks in patients after HSCT, it is 
important to develop very fast protocols for detection and expansion of ADV-specific T cells. 
In order to investigate the kinetics and earliest time points for detection of ADV-specific T 
cells, samples were harvested and subsequently frozen every day during the 12 days of  
expansion. Afterwards, all samples were thawed and analyzed by flow cytometry using ADV-
specific pentamers. In all three donors the highest number of ADV-specific T cells/µl was 
found after 12 days of expansion (Figure 10F and G). Strikingly, ADV-specific T cells were 
already detected after 5-6 days of expansion (Figure 10F and G). Figure 1G shows the 
average of ADV-pentamer+ T cells in cells/µl and percentage of CD8+ T cells of all 3 donors, 
implying a correlation between both types of analysis.  
These results indicate that our in vitro expansion protocol allows rapid generation and 
therefore clear detection of ADV-specific T cells in healthy donors. 
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Figure 10. Generation and detection of ADV-specific T cells. 
ADV-specific T cells of donor PBMCs before expansion and after expansion were analyzed by 
MHC I restricted ADV-specific pentamer. For expansion, PBMCs were stimulated with the ADV-
PepTivator on day 0 and restimulated with monocytes on day 6. On day 3 and 9, IL-15 was added 
to the culture.  
(A) Analysis of ADV-specific T cells before (day 0) and after expansion (day 12). One 
representative experiment is shown. Cells were analyzed with an unmatched MHC I ADV 
pentamer to determine the background level (first row) and with the matched pentamer (second 
row). ADV-specific T cells/µl are shown in the gate represented on each dot plot. Analysis of 
ADV-specific T cells of 11 donors on day 0 and day 12 are shown in cells/µl (B) and in 
percentages of CD8+ T cells (D). The average of ADV-specific T cells of different donors on day 0 
and day 12 analyzed in cells/µl (C) and percentage of CD8+ cells (E) are shown. The 
summarizing diagrams show means ± SEM of 11 healthy donors on day 0 and day 12. The 
number of ADV-specific T cells/µl of 3 different donors were analyzed every day during the 
expansion period (F). (G) A summarizing diagram including the number of ADV-specific T cells/µl 
(black circles) and percentages of CD8+ T cells (white bars) of all 3 donors are shown in means ± 
SEM. 
 
 
Figure 11. Influence of IL-2, IL-7 and IL-15 on the expansion of ADV-specific T cells. 
PBMCs of 8 different donors were cultured for 12 days with PepTivator ADV as described (2.2.1.4 
Expansion of ADV-specific T cells (in vitro cell stimulation)). On day 3 and 9 cells were either 
untreated (-IL) or treated with IL-2, IL-7, or IL-15 as indicated. 
(A) One representative blot is shown. ADV-specific pentamer+ T cells/µl are shown in the gate 
represented on each dot plot. (B) A summarizing diagram shows means ± SEM of ADV-specific T 
cells after treatment with different interleukins as indicated. Significance versus untreated ADV-
specific T cells: n.s., non significant; *, P ≤ 0.05. 
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3.1.2 Influence of different interleukins on the expansion of ADV-specific T cells 
Interleukins (IL), a subgroup of cytokines, play a major role in vitro and in vivo in the 
maintenance and development of different cell types.  
To evaluate the effect of interleukins on the expansion of 12 days cultured ADV-specific T 
cells, cells were either untreated or treated with IL-2, IL-7 or IL-15 on day 3 and 9. 
Surprisingly, neither IL-2 nor IL-7 showed significantly increased expansion of ADV-specific T 
cells/µl compared to untreated samples. In contrast, treatment with IL-15 significantly 
increased (3,5 fold) the number of ADV-specific T cells/µl after 12 days of expansion (Figure 
11A and B).  
These results revealed that IL-15 seems to be the most efficient interleukin for rapid 
expansion of ADV-specific T cells. 
 
3.1.3 Phenotypic characterization of T cells 
3.1.3.1 Phenotypic characterization of T cell populations before and after the 
expansion period  
To further evaluate the influence of the expansion period on the phenotype of different T cell 
subpopulations, immunophenotype staining was performed by flow cytometry. Previous data 
have described four different populations of T cells, termed naïve (CD62L+ CD45RA+), 
central memory (TCM; CD62L+ CD45RA-), effector memory (Teff; CD62L- CD45RA-), and 
CD45RA+ effector memory T cells (Temra; CD62L- CD45RA+). Particularly central memory 
T cells are known to mediate long-term immunity and could therefore be highly relevant  for 
adoptive T cell therapies. First we determined the immunophenotype of CD4+ and CD8+ T 
cells on day 0 and day 12 after expansion. As shown in Figure 12A, CD4+ T cells analyzed 
on day 0 showed no significant differences in the TCM subpopulation compared to day 12 
(24.3% vs 27.9%). In contrast, the Teff population was significantly increased (38.7% vs 
60.6%) whereas the naïve (22.8% vs 10.8%) and Temra (14.2% vs 0.7%) populations were 
reduced after 12 days of expansion (Figure 12 A). In CD8+ T cells, the TCM population was 
significantly increased (9.8% vs 22.1%, P=0.0049) after 12 days of expansion compared to 
day 0. Similar to the results of CD4+ T cells, the mean number of naïve (21.7% vs 16.8%) 
and Temra (29.3% vs 4.1%) populations was reduced after 12 days of expansion whereas 
the mean number of the Teff population (39.2% vs 57.1%; P=0.0461) was significantly 
increased (Figure 12 B). 
Next, we analyzed the percentages of different subpopulations of pentamer+ ADV-specific T 
cells on day 0 and day 12. As the frequency of ADV pentamer+ T cells was very low on day 0 
(Figure 10), ADV-specific pentamer+ T cells were enriched by MACS technology as 
described in materials and methods. The number of pentamer+ T cells/µl after magnetical 
enrichment was more than 3 log increased compared to that of freshly isolated PBMCs. 
3 Results 
42 
Similar results were seen by analyzing the percentage of ADV-specific T cells in CD8+ T 
cells. Additionally, ADV-specific T cells were analyzed in cells/µl and percentage of CD8+ T 
cells. In both cases, ADV-specific T cells were 1 to 2 log increased after 12 days of 
expansion (Table 4). 
 
Table 4. ADV-specific T cells on day 0, on day 0 after enrichment and after expansion on 
day 12.  
 
ADV-specific  
T cells 
% ADV-specific 
T cells of CD8+ T cells 
day 0  0.23 (0.1-0.4) /µl 0.6 (0.01-0.37) 
day 0 enrichment 752,4(164.6-1628.6) 18.5 (0.11-45.16) 
day 12  65.8 (18.6-102.8) /µl 20.6 (6.3-42.9) 
 
As shown in Figure 12C, magnetically enriched ADV-specific pentamer+ T cells analyzed on 
day 0 showed significantly reduced TCM populations (46.3% vs 2.8%) compared to day 12. 
As expected, naïve and Temra populations were decreased whereas Teff populations 
(41.2% vs 96.3%) were significantly increased after 12 days of expansion (Figure 12C). In 
one case (date not shown and not included) TCM of ADV-specific T cells increased (59.3% 
vs 73.8% of ADV-specific T cells) after expansion.  
Yet despite 12 days of expansion, TCM populations could still be detected, indicating that 
both Teff and TCM ADV-specific T cells could be generated. Additionally, as is well known, 
only few TCM cells are necessary for a lifelong protection against the ADV virus in patients 
after HSCT.  
 
3.1.4 The effect of interleukins on the immunophenotype of T cells during in vitro 
expansion 
Previous studies suggested that interleukins could play a role in the manifestation of virus-
specific memory or effector cells. To investigate the influence of different cytokines on the 
immunophenotype of T cells, addition of IL-2, -7, and -15 was attempted with regard to TCM, 
which could provide lifelong protection from viral disease as mentioned above. We analyzed 
the effect of different interleukins on the percentages of TCM, naïve, Teff, and Temra T cell 
populations in CD8+, CD4+, and ADV-specific pentamer+ T cells after 12 days of expansion. 
Surprisingly, treatment with different interleukins showed no significant influence on the 
percentage of TCM, naïve, Teff, and Temra T cells when gated on CD8+ T cells (Figure 
13A), CD4+ T cells (Figure 13B), and ADV-pentamer+ T cells (Figure 13C). The T cell 
subgroups CD8 and CD4, showed few differences in their phenotype analysis: The 
percentage of TCMs in CD4+ T cells was higher as compared to that of CD8+ T cells (CD4: 
31.6%, CD8:19.9%) and the percentage of Temra cells was higher in CD8+ T cells as 
compared with that of CD4+ T cells (CD4: 1.1%, CD8: 5.8%).  
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Although the percentage of TCMs in ADV-pentamer+ T cells was again reduced after 12 
days of expansion (35% vs 7.5%; data not shown), TCM T cells could nonetheless be 
detected. 
Taken together, the effects described in the literature could not be confirmed, interleukin 
treatment had no influence on the expansion of TCM T cell populations in our experimental 
setting.  
  
 
 
Figure 12. Immunophenotype analyses of different T cell subpopulations before and after 
in vitro expansion.  
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PBMCs of different donors were cultured for 12 days with ADV-PepTivator and IL-15 as described 
in material and methods. Cells were stained by the MHC I pentamer and immunophenotypical 
markers such as CD3, CD8, CD4, CD62L, and CD45RA were analyzed by flow cytometry. 
Central memory T cells (TCM) and effector T cells (Teff) were identified by their low or high 
expression of CD62L, respectively. Furthermore, CD45RA was used to distinguish between TCM 
and naïve T cells, Teff and effector memory RA+ T cell (Temra). Numbers in blots represent % of 
CD8, CD4 or ADV-specific T cells of the following phenotypes: TCM (CD45RA-, CD62L+), Naïve 
T cell (CD45RA+, CD62L+), Teff (CD45RA-, CD62L-), Temra (CD45RA+, CD62L-). For detailed 
phenotypical analysis, CD8+, CD4+, and pentamer+ T cells were gated.  
The percentage of TCM, naïve, Teff, and Temra T cell subpopulations of CD8+ T cells (A) and 
CD4+ T cells (B) on day 0 (gray bars) and day 12 (black bars) are shown. Data show means and 
SEM of 6 independent experiments. (C) The percentage of TCM, naïve, Teff, and Temra T cell 
subpopulations of magnetically enriched ADV-pentamer+ T cells on day 0 (gray bars) and ADV-
pentamer+ T cells on day 12 (black bars) are shown. Data show means and SEM of 4 
independent experiments.   
In some experiments, the gated dots vary as a consequence of their modification during the 
expansion process. Typical dot blots of CD8+, CD4+, and ADV-pentamer+ gated T cells out of 4 
to 6 donors are shown. Significance versus day 0 of different T cell populations (as indicated): 
n.s., non significant; o, P ≤ 0.11; *, P ≤ 0.05; **, P ≤0.01.  
 
 
 
Figure 13. Phenotype analysis of expanded CD8+, CD4+ and ADV-specific T cells under 
interleukin treatment.  
PBMCs were cultured in median for 12 days with PepTivator ADV as described in materials and 
methods. On day 3 and 9 cells were either untreated (-IL, white bars) or treated with IL-2 (light 
grey bars), IL-7 (dark grey bars), or IL-15 (black bars). All cell populations together represent 
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100%. TCM indicates CD45RA-, CD62L+ cells, naïve T cells CD45RA+, CD62L+, Teff CD45RA-, 
CD62L- and Temra CD45RA+, CD62L- cells. 
The percentage of TCM, naïve, Teff, and Temra cell populations of CD8+ T cells (A), CD4+ T 
cells (B) and ADV-pentamer+ T cells (C) treated with different interleukins (as indicated) are 
shown. The diagrams give means and SEM of 8 independent experiments. Significance vs. 
untreated (-IL) cells : n.s., non significant. 
 
 
 
3.2 Irradiated virus-specific T cells for adoptive immunotherapy after 
allogeneic hematopoietic stem cell transplantation 
We established a fast and reliable protocol for the expansion of ADV-specific T cells. 
However, although previous data showed that the alloreactivity of in vitro expanded ADV-
specific T cells seems to be significantly reduced as compared to PBMCs, the risk for GvHD 
after transfer into the patient could not be excluded. So in order to prevent cell proliferation 
and subsequently GvHD, transfusion products are irradiated in the daily hospital routine. 
Since little is known about irradiated T cells and their contribution in fighting against viral 
infections,32 we analyzed the viability, functional activity, and alloreactivity of ADV-specific T 
cells after irradiation.  
 
3.2.1 Viability of expanded ADV-specific T cells after irradiation 
The viability and functionality of ADV-specific T cells is one of the key points for successful 
application in the clinical setting. First we expanded ADV-specific T cells for 12 days as 
described (2.2.1.4 Expansion of ADV-specific T cells (in vitro cell stimulation)). Then the cells 
were untreated or irradiated with 30Gy and subsequently cultured for 24, 48, and 72 hours. 
The viability was assessed by flow cytometry using TrucountTM tubes, which enables the 
analysis of cells/µl. The samples were analyzed directly on day 0, 24h, 48h, and 72h after 
cell culture. The viability was compared to non-irradiated ADV-specific T cells at every time 
point of measurement. Generally, the viability of non-irradiated T cells was not affected by 
additional culture periods.  
Viable cells were identified by their size (SSC-A) and granularity (FSC-A) immediately after 
cell harvesting. A typical dot blot is shown in Figure 14, the yield of viable cells constituted 
2460/µl (non-irradiated) and reached 851/µl 72h after irradiation. As expected, the viability 
was affected by the process of irradiation. Nevertheless, 6h after irradiation treatment, still 
92% could be identified as viable cells (data not shown). After 24h, 49% viable cells were 
identified (non-irradiated: 86% viable cells), the same tendency could be observed after 48h 
with 24.2% viable cells. In fact, a slowdown could be detected after 72h, when 20.4% of the 
cells, compared with non-irradiated cells, showed indications of viability. Strikingly, even 24h 
after irradiation, no significant difference to that of non-irradiated samples was seen 
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(P=0.1206). After 48h (P=0.0214) and 72h (P=0.0208), however, a significance could be 
observed. 
Taken together, although ADV-specific T cells lose viability after irradiation treatment, at least 
20.4% of the cells are viable 72h after irradiation. These findings indicate that even 72h after 
irradiation, viable cells are detectable. 
 
Figure 14. Viability of irradiated ADV-specific T cells after different time points.  
PBMCs were stimulated with PepTivator ADV and treated with IL-15 as described in materials 
and methods. For each approach 5 x 105 expanded ADV-specific T cells were placed in a 96-well 
plate, either non-irradiated (non-irr) or irradiated (irr) with 30Gy (3000rad). Each well was 
completely harvested after 24h, 48h and 72h, at every time point non-irradiated cells were 
analyzed as control. Cells were transferred into TruCOUNTTM tubes and analyzed with flow 
cytometer LSRII.  
Viable cells were defined by gating forward scatter (FSC) vs side scatter (SSC). After 24h, 48h, 
and 72h two populations are visible: a vital cell population with unchanged scatter signals and an 
apoptotic cell population with decreased FSC and increased SSC signals. The percentage of 
viable cells was calculated as follows: (number of viable irradiated cells/µl) / (number of viable 
(sham) non-irradiated cells/µl) x 100. In all experiments, results were referred to the non-irradiated 
cells measured on day 0 (gray bar) which was set to 100%. Non-irradiated cells after 24h, 48h, 
and 72h are indicated as white bars, irradiated cells as black bars. Data show means ± SEM of 4 
independent experiments. Significance versus non-irradiated ADV-specific T cells at the time 
point of analysis: n.s., non significant; *, P ≤ 0.05. Typical dot blots out of 4 experiments are 
shown. Values indicate the living cells per µl in the gated area. 
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3.2.2 Effect of irradiation on the functional activity of ADV-specific T cell population  
Next, we analyzed the functional activity of non-irradiated and irradiated ADV-specific T cells. 
Therefore, after restimulation of already expanded ADV-specific T cells with the ADV-specific 
antigen (PepTivator), T cell activation markers such as INF-γ, CD137, and CD107a were 
analyzed by flow cytometry. 
 
To investigate the impact of irradiation on the functional activity of expanded ADV-specific T 
cells, after 12 days stimulation, cells were irradiated by 30Gy and cultured for 16h over night. 
As a positive control, non-irradiated cells were also cultured for 16h. On the following day, 
non-irradiated and irradiated ADV-specific T cells were either unstimulated (negative control) 
or restimulated for 4h with the superantigen (positive control; data not included in the 
diagram, showing means ± SEM) or the appropriate ADV-specific antigen (PepTivator). After 
4h of restimulation, the secretion of IFN-γ and the expression of CD107a of cells were 
analyzed at the same time by the IFN-γ cytokine secretion assay (CSA) according to 
manufacturers´ instructions. In all experiments, additional staining of CD3, CD4, and CD8  
were performed in order to be able to gate different T cell subpopulations.  
Strikingly, the percentage of IFN-γ secreting CD8+ T cells was significantly increased in both 
settings, the non-irradiated cells from 0.4% to 14.7% and the irradiated cells from 1.1% to 
12.0% after restimulation with the ADV-PepTivator (Figure 15A). Similar results were 
obtained by analyzing the non-irradiated (0.2% to 16.4%) and irradiated (0.5% to 17.5%) 
CD4+ T cells (Figure 15B). These results indicate that the IFN-γ secretion of CD4+ as well as 
CD8+ T cells was not significantly affected 16h after irradiation.  
Similarly, we analyzed the expression of CD107a, a marker for the cytotoxic activity of CD8+ 
T cells, within the same samples (Figure 15C). In accordance with the data shown in Figure 
15A, the expression of CD107a was induced in both the non-irradiated  - from 0.5% to 7.1% - 
as well as in the irradiated cells - from 1.0% to 3.9%. However, the reduced expression of 
CD107a after irradiation from 7.1% to 3.9% was not significant (Figure 15C).  
Next we analyzed the expression of CD137, another important T cell activation marker. Since 
the expression of CD137 was shown to be optimal after 16h of restimulation, cells were 
directly restimulated after irradiation. Although the background level (negative control, -) was 
relatively high, an induction of CD137 expression after restimulation was seen in CD8+ 
(Figure 15D) as well as in CD4+ (Figure 15E) T cells irrespective of irradiation. Again  no 
significant effect of irradiation was seen by comparing the percentage of CD137 expression 
of non-irradiated with that of irradiated CD8+ T cells (4.8% vs 10.1%) and CD4+ T cells 
(7.7% vs 11.3%). 
 
These results clearly indicate that the functional activity of CD8+ as well as CD4+ ADV-
specific T cells was not affected - at least not 16h after irradiation. 
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Figure 15. Functionality analysis of irradiated, expanded, ADV-specific T cells.  
Over 12 days PepTivator expanded PBMCs were irradiated by 30Gy and cultured for 16h over 
night. Non-irradiated cells were also cultured for 16h.  
Afterwards, non-irradiated and irradiated cell cultures were either unstimulated (negative control, - 
stimulation) or stimulated for 4h with either superantigen (positive control, SEB) or ADV-specific 
antigen (positive, ADV-stimulation). Staining was performed in combination with a cytokine 
secretion assay. For CD137 analysis, 16h stimulation represents the optimal duration. Therefore, 
stimulation starts at the same time point as irradiation treatment occurs.  
Representative dot blots show percentage of CD8 or CD4+ T cells. The first row represents non-
irradiated (non-irr), the second row 16h irradiated cells (irr). Diagram shows means ± SEM of 3-8 
independent experiments. The percentage of IFN-γ of CD8+ T cells (A) and CD4+ T cells (B); 
percentage of CD107a of CD8+ T cells (C); percentage of CD137 of CD8+ T cells (D) and CD4+ 
T cells (E) are shown. Significance: n.s., non significant; o, P ≤ 0,13; *, P ≤ 0.05; **, P ≤ 0.01. 
 
 
3.2.3 Effect of irradiation on the cytotoxic activity of ADV-specific T cells 
Generally, besides the ability of virus-activated T cells to produce IFN-γ and other activation 
markers, they can be cytotoxic, being able to lyse virus infected cells. In order to investigate 
the cytotoxicity of non-irradiated and irradiated expanded ADV-specific T cells, a newly 
developed cytotoxic Assay (CTA), based on flow cytometric analysis, was used to avoid the 
common radioactive chromium release assay. Therefore, non-irradiated and irradiated 
expanded ADV-specific T cells, were incubated with unpulsed (negative control), ADV-
peptide-pulsed or PepTivator-ADV5 Hexon-pulsed autologous target cells for 4h at a ratio of 
20:1 (T cell to target cell) to induce cytotoxic killing. To analyze the impact of irradiation on 
ADV-specific T cells after several hours, the cytotoxic assay was performed 6h, 24h, and 48h 
after irradiation. Induced cell death was determined by staining with DAPI and TrucountTM 
tubes.  
 
As shown in Figure 16, the number of dead cells/µl of unpulsed peptide-pulsed, and 
PepTivator-pulsed autologous target cells without the incubation of ADV-specific T cells 
ranged from 4.1-7.7/µl. Non-irradiated ADV-specific T cells showed increased specific lysis of 
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ADV-peptide (18.2 dead target cells/µl ± 2.9, P=0.0021) and PepTivator – pulsed (13.5 ± 2.2, 
P=0.0480) target cells compared to unpulsed target cells (5.8 ± 0.7). Also, the peptide-
specific (17.6 ± 2.3, P=0.0080) and PepTivator-specific (14.2 ± 2.3, p<0.0740) lysis of ADV-
specific T cells, 6h after irradiation was significantly higher as compared to the respective 
unpulsed target cells (5.2 ± 0.4). ADV-specific T cells 24h after irradiation still showed 
increased lysis of peptide-pulsed (10.2 ±1.3, P=0.0052) and PepTivator-pulsed (10.1 ± 2.9, 
P=0.0382) targets as compared to unpulsed targets (4.9 ± 0.5)  - even though the peptide-
specific lysis was not significant. Even 48h after irradiation, increased lysis of peptide-pulsed 
targets (11.6 ± 3.8, P=0.2400) as compared to unpulsed targets (6.2 ± 0.9) were seen 
(Figure 16).  
However, the increase of peptide-specific lysis induced by irradiated T cells was similar, or 
slightly lower, 6h (3.4 fold), 24h (2.1 fold), and 48h (1.9 fold) after irradiation, compared to 
non-irradiated T cells (3.1 fold). In addition, also the increase of PepTivator-specific lysis 
induced by irradiated T cells was similar, 6h (2.7 fold) and 24h (2.1 fold) after irradiation, as 
compared to non-irradiated T cells (2.3 fold). 48h after irradiation, no specific lysis was seen 
(results of a single experiment are shown). Notably, the corresponding numbers of apoptotic 
cells/µl of unpulsed target cells were very similar to each other. Taken together, these results 
clearly indicate that even after 6h, 24h, and 48h after irradiation, ADV-specific T cells are still 
cytotoxic against ADV-pulsed target cells.  
 
Focusing on the affect of target pulsed with peptide or PepTivator, the former achieved 
higher success rates, independent of the irradiation status. The incidence of the higher killing 
frequency for peptide pulsed target cells is still unclear, but there is evidence that ADV-
PepTivator needs longer incubation time for a perfect presentation on the MHC I receptor. 
 
 
 
 
 
Specific lysis was tested using autologous PHA blasts (target) pulsed with either ADV-PepTivator 
(TP PepTivator) or peptide ADV (TP peptide), as control unpulsed autologous targets (TuP) were 
used. As effectors, over 12 days PepTivator stimulated ADV-specific T cells, either non-irradiated 
(non-irr) or irradiated (irr, 6, 24, 48h before the assay) was applied. An effector-target ratio of 20:1 
was observed. After 4h incubation, cells were analyzed by flow cytometer, whereas dead target 
cells/µl were displayed.  
(A) Dot blots of one representative donor out of 6 experiments are shown. The first vertical row 
represents the FSC/SSC from peptide pulsed target cells with effector cells. Horizontal the 
different time points after irradiation of effector cells is indicated. (B) Summary of 1-6 independent 
experiments. Dashed bars indicate unpulsed targets, either with effectors or without, black bars 
represent targets pulsed with peptide ADV and grey bars with ADV-PepTivator. Data show means 
and SEM. Significance target unpulsed vs pulsed target cells: o, P ≤ 0.1; *, P ≤ 0.05; **, P ≤ 0.01.  
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Figure 16. Cytotoxic assay of irradiated ADV-specific T cells.  
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3.2.4 Clinical Applications 
3.2.4.1 Frozen expanded ADV-specific T cells show no quality reduction  
Although real-time PCR analysis permits early detection of impending invasive viral-infection 
in patients after HSCT, the exact time point and need for a T cell immunotherapy in the daily 
clinical practice is often influenced by unexpected complications and changes in treatment 
schemas and is mostly unpredictable. Therefore, prophylactic generation and freezing of 
virus-specific T cells followed by thawing, irradiation and administration of such cells after the 
occurrence of invasive viral infections in patients could provide an attractive treatment option.  
 
In order to test the effect of freezing and thawing on the cytotoxicity of ADV-specific T cells 
following irradiation, unfrozen and frozen expanded ADV-specific T cells were analyzed by 
flow cytometry. After thawing, cells were cultured for one day to optimize their viability 
performance. Afterwards, a CTA was performed.  
Because very high numbers of PBMCs are needed, only one single experiment could have 
been performed.  
The induced specific lysis of peptide-pulsed target cells by non-irradiated unfrozen ADV-
specific T cells (11.9 dead target cells/µl) was comparable to that of frozen ADV-specific T 
cells (10.9 dead target cells/µl). Also, freezing did not have any effect on the cytotoxicity of 
ADV-specific T cells 24h after irradiation (Figure 17). However, in this experiment, the 
irradiated ADV-specific T cell population showed only a slightly increased lysis of peptide-
pulsed target cells (6.2 dead target cells/µl) compared to unpulsed target cells (4.6 dead 
target cells/µl), which might be explained by the intra-individual variability of donors.  
Thus, in this experiment, a clear conclusion whether freezing is influencing the functional 
activity of irradiated T cells was not possible and needs to be further investigated. 
 
These results indicate that freezing does not influence the cytotoxicity of non-irradiated 
expanded ADV-specific T cells. 
 
3.2.4.2 Analysis of alloreactivity of non-irradiated and irradiated expanded ADV-
specific T cells  
The adoptive transfer of ADV-specific T cells into mismatched recipients increases the risk 
for GvHD in patients. According to the literature, ADV-specific T cells are described to 
recognize only ADV-infected cells because of the expression of restricted ADV-specific TCR 
receptors. Therefore, the cytotoxic assay was performed by incubating non-irradiated or 
irradiated generated ADV-specific T cells of one donor (a) with that of autologous (A), 
partially mismatched by including at least 1 matched locus of HLA I (B and C) or completely 
mismatched (D) target cells.  
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Figure 17. Cytotoxic assay of frozen and non-frozen expanded ADV-specific T cells in 
comparison. 
Specific lysis was tested with autologous peptide ADV pulsed PHA target cells (TP peptide), as 
control unpulsed autologous targets (TuP) were used. As effector cells, expanded ADV-specific T 
cells were severed, either non-frozen (grey bars) or frozen (black bars), furthermore half of them 
were irradiated 24h before the assay (24h irr), the others were used as non-irradiated control 
(non-irr). Result of one experiment is shown at an effector-target ratio of 20:1, whereas dead 
target cells/µl are illustrated.  
 
 
Comparable to the results seen in Figure 16, the specific lysis of autologous peptide-pulsed 
target cells is similarly induced by non-irradiated (bar 4: 13.4 dead cells/µl) and irradiated 
(bar 6: 8.2 dead cells/µl) ADV-specific T cells as compared to the respective unpulsed target 
cells (bar 3: 3.7 dead cells/µl; bar 5: 3.4 dead cells/µl) (Figure 18). Next, we assessed the 
alloreactivity of donor ADV-specific T cells in the partially (B and C) and completely 
unmatched (D) setting. Strikingly, the specific lysis of unpulsed autologous control target cells 
(bar 3: 3.7 dead cells/µl) was only slightly induced or even reduced as compared to the 
partially mismatched target cells of recipient B (bar 9: 5.4 dead cells/µl) and C (bar 15: 4.3 
dead cells/µl) and the completely mismatched target cell of recipient C (bar 21: 2.9 dead 
cells/µl). These data indicate that the alloreactivity of expanded ADV-specific T cells was 
highly reduced in most mismatched recipients. As already shown in Figure 16, the 
background lysis generally ranged from 3 to 7 cells/µl.  
3 Results 
54 
However, although generated ADV-specific T cells should not be alloreactive, killing of ADV-
infected cells in partially matched recipients, as it is the case after haploidentical HSCT, is 
desirable. To resemble this in vivo situation, the cytotoxicity of ADV-specific T cells against 
partially mismatched target cells (B and C) was analyzed. In fact, the specific lysis of ADV-
pulsed target cells of recipient B was increased as compared to the unpulsed target cells (bar 
10: 12.7 dead cells/µl vs bar 9: 5.4 dead cells/µl, respectively). A slightly increased 
cytotoxicity was also seen in the ADV-pulsed target cells of recipient C as compared to 
unpulsed target cells (bar 16: 6.3 dead cells/µl vs bar 15: 4.3 dead cells/µl, respectively). 
Strikingly, at least in recipient B also irradiated ADV-specific T cells showed specific lysis of 
ADV-pulsed target cells as compared to unpulsed target cells (bar 12: 8.7 dead cells/µl vs 
bar 11: 5.2 dead cells/µl, respectively).  
Although the alloreactivity of generated ADV-specific T cells was very low or even not 
existent, alloreactivity can only be completely excluded by additional irradiation. The fact that, 
despite irradiation, ADV-specific T cells are still able to kill virus-infected target cells also in a 
partially mismatched setting, opens a new window for adoptive T cell immunotherapies and 
would even allow the infusion of third party ADV-specific T cells without the risk for GvHD. In 
the clinical situation, non-irradiated and irradiated cells could be used, depending on the 
number of mismatched HLA types between donor and recipient, which is known to correlate 
with the risk for GvHD. 
 
Figure 18. Alloreactivity: specific lysis of allogeneic pulsed target cells.  
Expanded ADV-specific T cells, irradiated and non-irradiated serve as effector cells (a). As target 
cells PHA blast from 4 different donors, autologous (A) and allogeneic (B,C,D) were either non 
pulsed (dashed bars) or pulsed with peptide ADV (filled bars). Shown are triplicates of 4 different 
experiments. 
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4 Discussion 
Considerable progress of HSCT techniques has led to significantly higher survival rates of 
patients who either receive T cell-depleted products or who require more intensive and 
prolonged post-transplant immune-suppression. On the other hand, however, an increasing 
number of patients contract severe or lethal adenovirus infections during the post-transplant 
phase after HSCT. So far, current pharmacological strategies for preemptive and acute 
therapies are insufficient and limited by significant side effects. Evidence indicating that 
recovery of ADV-specific T cells correlates with the clearance of ADV infections36,37 prompted 
us to develop a protocol for detection and generation of ADV-specific T cells. 
 
Expansion and characterization of in vitro-generated ADV-specific T cells 
 
The frequency of ADV-specific T cells is very low in freshly isolated peripheral blood (0.2 ± 
0.03 cells/µl or 0.1% ± 0.03 of CD8+ T cells) and is quite often below the limit of detection. 
Therefore, to increase the frequency of ADV-specific T cells, additional, fast in vitro 
expansion for 12 days was performed resulting in a 1 to 2 log increase of ADV-specific T 
cells. In order to define the earliest time point for detection of ADV-specific T cells, pentamer 
staining was performed each day. We could demonstrate that a first clear detection of ADV-
specific T cells was even possible on day 6 of expansion followed by a decrease on day 8 
and 9. This could, however, easily be explained by the fact that after restimulation on day 6, 
T cell receptor (TCR) internalization occurs, which reduces the binding of multimers to the 
TCR.38,39 
Several groups tried different strategies to isolate ADV-specific T cells. Comoli et al. 
cultured PBMCs for 4 weeks to achieve an 2.5 fold increase of ADV-specific T cells.40 
Another very time consuming and costly expansion protocol (6 weeks), including repeated in 
vitro stimulation by antigen-pulsed dendritic cells, was developed by Leen et al.35 In contrast 
to these time consuming protocols, Feuchtinger et al. and Aïssi-Rothé et al. established a 
method where IFN-γ secreting ADV-specific T cells could be directly isolated after a magnetic 
selection process.6,41 However, since only very low frequencies of ADV-specific T cells are 
present in fresh blood, large starting blood volumes are necessary for such therapies. 
Additionally, isolation of virus-unspecific IFN-γ producing T cells cannot be excluded, which 
bears the risk of GvHD. A combination of both methods, where first IFN-γ producing T cells 
were magnetically isolated followed by in vitro expansion, showed a 1-2 log increase of ADV-
specific T cells within 2 weeks.13,35 However, again large starting blood volumes, which are 
often not available, are necessary for such therapies. Therefore, we reasoned that our fast 
repeated in vitro stimulation without the need of large blood volumes, would fulfill all 
requirements for a safe and efficient strategy. 
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Next, on the basis of our encouraging results, we wanted to further optimize our 
protocol. It is known that different cytokines influence the process of T cell expansion and 
maturation in vivo and in vitro. Feuchtinger et al., for example, used IL-2 for expansion of 
isolated ADV-induced INF-γ producing cells.6 Another group also used IL-2 for expansion of 
ADV-specific T cells.40 In contrast, Fujita et al. achieved the best expansion results by either 
treatment with IL-15 alone or with a combination of IL-7, IL-12 and IL-15 (per 5ng/ml).42 We 
therefore tested the influence of IL-2, IL-7, and IL-15 on the expansion and the 
immunophenotype of ADV-specific T cells. Surprisingly, whereas treatment with IL-15 
significantly increased (3.4 fold) the expansion of ADV-specific T cells as compared to 
untreated cells, treatment of IL-2 and IL-7 showed no influence. This result could be 
explained by the fact that, in contrast to other groups, PBMCs were treated with cytokine for 
only a short period of time (day 3 to 6 and day 9 to 12). However, that cytokine treatment is 
not necessarily needed for T cell expansion, was also shown by Zandvliet et al.43 Their 
strategy, by the way, could also help to reduce the costs for immunotherapies.  
 
Beside the effect of cytokines on the expansion of T cells, they are also known to 
influence the effector/memory surface phenotype of cultured cells.44,45 Thus, we compared 
the surface phenotype of PBMCs at day 0 with that of 12 days expanded ADV-specific T 
cells, which were additionally treated with IL-15. As expected, the number of naïve and 
central memory T cells was reduced, whereas the number of effector ADV-specific T cells 
had increased. These results mimic the in vivo situation, where mostly effector T cells are 
necessary to fight against an acute infection. An increased number of effector T cells during 
the expansion period was also observed by other groups.13,43,46 Obar et al. demonstrated that 
in vivo IL-2–derived signals promote the downregulation of CD62L and formation of the 
effector memory T cell (TEM) population, whereas IL-15–derived signals promote the 
expression of CD62L and formation of central memory T cells (TCM) within the culture.44 We 
could, however, not observe an increase of TCMs after treatment with IL-15. Nevertheless, 
about 2,8% of TCMs, providing long-lived immunity, were maintained after the expansion 
period. Interestingly, treatment with IL-2, IL-7, and IL-15 showed similar results concerning 
the effector/memory phenotype after the expansion period. These results could again be 
explained by the short treatment period. However, avoidance of early interleukin treatment is 
indispensable to exclude the expansion of virus-unspecific T cells, which could result in a 
higher risk of GvHD. Summarizing these results, we could show that after expansion, high 
numbers of effector T cells and low numbers of TCMs had been be generated or maintained, 
respectively.  
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Irradiated ADV-specific T cells for adoptive immunotherapy after allogeneic 
hematopoietic stem cell transplantation 
 
Although several groups could show reduced alloreactivity of in vitro expanded ADV-specific 
T cells,13,17,40 a risk of GvHD in vivo can never be definitely excluded. To overcome this 
limitation for immunotherapies, the effect of irradiation of expanded ADV-specific T cells was 
analyzed.  
In the 1990s, it became clear that the lethality of tissue cells after radiation is rather 
due to activation of apoptosis than to irreversible damage of cells.47,48 Indeed, lymphocytes 
have been found to be among the most radiosensitive mammalian cells.49 However, another 
study showed that the sensitivity of T cells to irradiation could be reduced, when already 
stimulated T cells were used.50,51 A further hint, that irradiation is not completely inhibiting T 
cells, was shown in a case report by Witt et al.32 In this work, a clearance of CMV infection in 
a CMV seronegative patient after receiving irradiated fractions of granulocytes, including T 
cells of a CMV seropositive donor, suggested for the first time that even irradiated T cells 
could have been responsible for this effect - although definite evidence was missing.  
Therefore we first tested the effect of irradiation on ADV-specific T cells after 
expansion. Strikingly, although the viability of cells was decreased after irradiation, still about 
25% of cells proved highly vital. Since it is suggested that virus-specific T cells need about 1-
2 days to find and kill virus-infected cells, even irradiated cells should have enough time to 
fulfill their task before dying. A hallmark of T cells is their ability to secrete IFN-γ and express 
activation markers such as CD137 and CD107a after getting stimulated by viral antigens. 
Strikingly, restimulation of ADV-specific T cells 24h after irradiation showed similar secretion 
of IFN-γ and expression of CD137 compared to non-irradiated cells. In addition, the 
expression of CD107a, representing the cytotoxic potential of these cells,19 was also not 
decreased after irradiation, indicating that irradiation did not alter their functional activity.  
To mimic the cytotoxicity of ADV-specific T cells in vivo, an in vitro cytotoxic assay 
was performed. Thereby the ability of irradiated ADV-specific T cells to kill antigen-pulsed 
target cells (PHA blasts) was analyzed. We could clearly demonstrate that adenovirus-
specific lysis of target cells was induced 6h, 24h, and even 48h after irradiation. Interestingly, 
the number of killed target cells was lower when cells had been pulsed with the PepTivator 
as compared to peptide-pulsed cells. This result was surprising because PepTivator-pulsed 
target cells can be killed by CD4 and CD8+ T cells, whereas peptide-pulsed target cells can 
only be killed by the appropriate peptide-recognizing CD8+ T cells. We suggest that the 
lower concentration of the appropriate peptide within the peptide pools (PepTivator) could be 
the reason for these differences.  
Taken together, these results indicate that, despite irradiation, ADV-specific T cells 
are still functionally active and able to kill virus-infected cells.  
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Clinical applications 
In the clinical situation, the median time span between the detection of ADV loads in stool 
probes of patients after HSCT and first observation of lethal symptoms is approximately 21 
days.11 Therefore, depending on either a long culture process34,35 or fast magnetic isolation,52 
only prophylactic treatment or treatment on demand of patients with ADV-specific T cells 
have been reported, respectively. Since we could generate ADV-specific T cells within 12 
days, both options, prophylactic treatment as well as treatment on demand, are conceivable. 
However, for some patients, even the generation of ADV-specific T cells within 12 days 
would take too long. To overcome this problem, preemptive generation and freezing of ADV-
specific T cells, which could then be thawed and infused on demand, could be a possible 
approach. For this reason we analyzed the viability and functional activity of non-irradiated 
and irradiated ADV-specific T cells, after freezing and thawing. Strikingly, non-irradiated 
ADV-specific T cells showed similar cytotoxicity against peptide-pulsed target cells, 
regardless of whether the cells had been frozen or not. Since in this experiment, irradiated T 
cells showed only a slight induction of specific target cell lysis, a clear statement about the 
effect of irradiation on thawed T cells was not possible.  
Since for most patients, a matched donor is often not available, T cells have to be 
generated from mismatched donors, bearing, however, the risk of GvHD. To minimize this 
risk, the efficacy of T cells to kill allogeneic, partially unmatched and completely unmatched 
ADV-pulsed target cells was analyzed. Indeed, the alloreactivity of non-irradiated ADV-
specific T cells was very low and even absent after irradiation. These data are in accordance 
with studies by Leen et al. and Comoli et al.,35,40 who showed less alloreactivity of ADV-
specific T cells after in vitro expansion. However, apart from the loss of alloreactivity, cells 
must be able to kill virus-infected target cells even in allogeneic recipients where at least one 
HLA locus is matched. Consequently, we analyzed whether expanded ADV-specific T cells 
from one donor are able to kill peptide-pulsed target cells of partially mismatched recipients. 
Interestingly, the killing of partially mismatched target cells was similar to that of autologous 
target cells, representing a specific HLA-type dependent lysis in an allogeneic setting. 
Therefore, we assume that in a mismatched clinical setting, our in vitro expanded non- and 
irradiated ADV-specific T cells would be able to kill only specifically virus-infected cells. 
Based on our results, we suggest preemptive generation of ADV-specific T cells followed by 
freezing, which would allow the establishment of a library of ADV-specific T cells from even 
third party donors with decreased alloreactivity, which could then be infused on demand. The 
need for irradiation of ADV-specific T cells would depend on the donor/recipient matching.  
We have thus established a rapid, simplified and reliable method for the detection 
and generation of ADV-specific T cells that can be easily translated into a good 
manufacturing practice (GMP)-conform therapy as required for manipulation of cells prior to 
infusion into immunocompromised patients.  
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6.3 List of Abbreviations 
ADV, AdV Adenovirus 
APC Antigen-presenting cell 
APC Allophycocyanin 
CCRI Children´s Cancer Research Institute 
CD Cluster of differentiation  
CFSE Carboxyfluorescein diacetate 
CMV Cytomegalovirus  
CSA Cytokine secretion assay (CSA) 
CTA Cytotoxic assay  
DAPI 4',6-diamidino-2-phenylindole 
DLI Donor-leukocyte infusion  
EBV Epstein-Barr virus  
EDTA Ethylenediaminetetraacetic acid 
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FSC-A/W Forward side scatter area/wide 
G-CSF Granulocyte colony-stimulating factor 
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MACS Magnetic cell sorting 
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SCT Stem cell transplantation 
SEB Staphylococcal enterotoxin B  
SEM Standard error of the mean 
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TuP Target unpulsed 
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